Targeting HER2 for the treatment of breast cancer

Annual Review of Medicine

Volumn 66, Issue , 2015, Pages 111-128

  Rimawi, Mothaffar F ^a   Schiff, Rachel ^a   Osborne, C Kent ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

carcinoma of the breast; ErbB2; lapatinib; pertuzumab; resistance; T DM1; trastuzumab

Indexed keywords

AFATINIB; ALKYLATING AGENT; ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GEMCITABINE; LAPATINIB; LETROZOLE; MUCIN; NAVELBINE; NERATINIB; PACLITAXEL; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE; TAXANE DERIVATIVE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNINDEXED DRUG; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; NITRILE; QUINAZOLINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CARDIOMYOPATHY; CARDIOTOXICITY; DIARRHEA; DIMERIZATION; DRUG CONJUGATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HEART DISEASE; HUMAN; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN FUNCTION; RASH; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CARCINOMA; FEMALE; METABOLISM;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CARCINOMA; FEMALE; HUMANS; NITRILES; QUINAZOLINES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TRIAZOLES;

EID: 84921377658     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-042513-015127     Document Type: Article

References (100)

1. Citri A, Yarden Y. 2006. EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell Biol. 7:505-16
2. Nahta R, Yuan LX, Zhang B, et al. 2005. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 65:11118-28
3. Maroun CR, Rowlands T. 2014. TheMet receptor tyrosine kinase: a key player in oncogenesis and drug resistance. Pharmacol. Ther. 142:316-38
4. Schiff R, Massarweh SA, Shou J, et al. 2004. Cross-Talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin. Cancer Res. 10:331S-36S
5. TheCancerGenomeAtlas Network. 2012. Comprehensivemolecular portraits of human breast tumours. Nature 490:61-70
6. Berns K, Horlings HM, Hennessy BT, et al. 2007. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395-402
7. Weinstein IB, Joe A. 2008. Oncogene addiction. Cancer Res. 68:3077-80
8. Pegram M, Hsu S, Lewis G, et al. 1999. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18:2241-51
9. Pietras RJ, Pegram MD, Finn RS, et al. 1998. Remission of human breast cancer xenografts on therapy with humanizedmonoclonal antibody to HER-2 receptor andDNA-reactive drugs. Oncogene 17:2235-49
10. Harari D, Yarden Y. 2000. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 19:6102-14
11. Ghosh R, Narasanna A, Wang SE, et al. 2011. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res. 71:1871-82
12. Bates M, Sperinde J, Kostler WJ, et al. 2011. Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab. Ann. Oncol. 22:2014-20
13. Clynes RA, Towers TL, Presta LG, Ravetch JV. 2000. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6:443-46
14. Vogel CL, Cobleigh MA, Tripathy D, et al. 2002. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20:719-26
15. Cobleigh MA, Vogel CL, Tripathy D, et al. 1999. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17:2639-48
16. Slamon DJ, Leyland-Jones B, Shak S, et al. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344:783-92
17. Sheth S, Pal SK, Pegram M. 2014. Treatment of HER2-overexpressing metastatic breast cancer. In Diseases of the Breast, ed. JR Harris, ME Lippman, M Morrow, CK Osborne, pp. 960-73. Philadelphia: Wolters Kluwer/LippincottWilliams & Wilkins. 5th ed.
18. Giordano SH, Temin S, Kirshner JJ, et al. 2014. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 32:2100-8
19. Burstein HJ, Storniolo AM, Franco S, et al. 2008. A phase II study of lapatinib monotherapy in chemotherapy-refractoryHER2-positive and HER2-negative advanced ormetastatic breast cancer. Ann. Oncol. 19:1068-74
20. Geyer CE, Forster J, Lindquist D, et al. 2006. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355:2733-43
21. Cameron D, Casey M, Press M, et al. 2008. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res. Treat. 112:533-43
22. Guan Z, Xu B, DeSilvio ML, et al. 2013. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. J. Clin. Oncol. 31:1947-53
23. Blackwell KL, Burstein HJ, Storniolo AM, et al. 2012. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positivemetastatic breast cancer: final results from the EGF104900 study. J. Clin. Oncol. 30:2585-92
24. Zhang X, Munster PN. 2014. New protein kinase inhibitors in breast cancer: afatinib and neratinib. Expert Opin. Pharmacother. 15:1277-88
25. Herter-Sprie GS, Greulich H, Wong KK. 2013. Activating mutations in ERBB2 and their impact on diagnostics and treatment. Front. Oncol. 3(Article 86):1-10
26. Cortes J, Fumoleau P, BianchiGV, et al. 2012. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 30:1594-600
27. Baselga J, Cortes J, Kim SB, et al. 2012. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366:109-19
28. Swain SM, Kim SB, Cortes J, et al. 2013. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 14:461-71
29. Nahta R, O'Regan RM. 2012. Therapeutic implications of estrogen receptor signaling inHER2-positive breast cancers. Breast Cancer Res. Treat. 135:39-48
30. Kaufman B, Mackey JR, Clemens MR, et al. 2009. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J. Clin. Oncol. 27:5529-37
31. Johnston S, Pippen J Jr, Pivot X, et al. 2009. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J. Clin. Oncol. 27:5538-46
32. Burris HA 3rd, Rugo HS, Vukelja SJ, et al. 2011. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J. Clin. Oncol. 29:398-405
33. Krop IE, LoRusso P, Miller KD, et al. 2012. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positivemetastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J. Clin. Oncol. 30:3234-41
34. Krop IE, Kim SB, Gonzalez-Martin A, et al. 2014. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, openlabel, phase 3 trial. Lancet Oncol. 15:689-99
35. Verma S, Miles D, Gianni L, et al. 2012. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367:1783-91
36. Hurvitz SA, Dirix L, Kocsis J, et al. 2013. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patientswith human epidermal growth factor receptor 2-positivemetastatic breast cancer. J. Clin. Oncol. 31:1157-63
37. Romond EH, Perez EA, Bryant J, et al. 2005. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353:1673-84
38. Romond E, Suman V, Jeong J-H, et al. 2012. Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: final planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. Proc. Thirty-Fifth Annual CTRC-AACR San Antonio Breast Cancer Symp., Cancer Res. 72(Suppl.):Abstr. S5-5
39. Piccart-GebhartMJ, ProcterM, Leyland-Jones B, et al. 2005. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353:1659-72
40. Spielmann M, Roche H, Delozier T, et al. 2009. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J. Clin. Oncol. 27:6129-34
41. Goldhirsch A, Piccart-Gebhart MJ, Procter M, et al. 2012. HERA trial: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up. Proc. Thirty-Fifth Annual CTRC-AACR San Antonio Breast Cancer Symp., Cancer Res. 72(Suppl.):Abstr. S5-2
42. Goldhirsch A, Gelber RD, Piccart-GebhartMJ, et al. 2013. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 382:1021-28
43. Pivot X, Romieu G, Debled M, et al. 2013. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol. 14:741-48
44. Joensuu H, Bono P, Kataja V, et al. 2009. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J. Clin. Oncol. 27:5685-92
45. Slamon D, Eiermann W, Robert N, et al. 2011. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 365:1273-83
46. Tolaney SM, Barry WT, Dang, CT, et al. 2013. A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). Proc. Thirty-Sixth Annual CTRC-AACR San Antonio Breast Cancer Symp., Cancer Res. 73(Suppl.):Abstr. S1-04
47. Buzdar AU, Ibrahim NK, Francis D, et al. 2005. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J. Clin. Oncol. 23:3676-85
48. Untch M, Rezai M, Loibl S, et al. 2010. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J. Clin. Oncol. 28:2024-31
49. Gianni L, Eiermann W, Semiglazov V, et al. 2014. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol. 15:640-47
50. SpectorNL, Blackwell KL. 2009. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 27:5838-47
51. Esteva FJ, Yu D, Hung MC, Hortobagyi GN. 2010. Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat. Rev. Clin. Oncol. 7:98-107
52. Rexer BN, Arteaga CL. 2012. Intrinsic and acquired resistance to HER2-Targeted therapies in HER2 gene-Amplified breast cancer: mechanisms and clinical implications. Crit. Rev. Oncol. 17:1-16
53. Arteaga CL, Sliwkowski MX, Osborne CK, et al. 2012. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat. Rev. Clin. Oncol. 9:16-32
54. De P, Hasmann M, Leyland-Jones B. 2013. Molecular determinants of trastuzumab efficacy: What is their clinical relevance?. Cancer Treat. Rev. 39:925-34
55. Whenham N, D'Hondt V, Piccart MJ. 2008. HER2-positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies. Clin. Breast Cancer 8:38-49
56. Arribas J, Baselga J, Pedersen K, Parra-Palau JL. 2011. p95HER2 and breast cancer. Cancer Res. 71:1515-19
57. Castiglioni F, Tagliabue E, Campiglio M, et al. 2006. Role of exon-16-deleted HER2 in breast carcinomas. Endocrine-Related Cancer 13:221-32
58. Bose R, Kavuri SM, Searleman AC, ShenW, Shen D, et al. 2013. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 3:224-37
59. Prempree T, Wongpaksa C. 2006. Mutations ofHER2 gene inHER2-positive metastatic breast cancer. J. Clin. Oncol. 24(18S):Abstr. 13118
60. Rimm D, Ballman KV, Cheng H, et al. 2012. EGFR expression measured by quantitative immunofluorescense is associated with decreased benefit from trastuzumab in the adjuvant setting in the NCCTG (Alliance) N9831 trial. Proc. Thirty-Fifth Annual CTRC-AACR San Antonio Breast Cancer Symp., Cancer Res. 72(Suppl.):Abstr. S5-4
61. Nahta R, Shabaya S, Ozbay T, Rowe DL. 2009. Personalizing HER2-Targeted therapy in metastatic breast cancer beyond HER2 status: What we have learned from clinical specimens?. Curr. Pharmacogenomics Personalized Med. 7:263-74
62. Arpino G, Gutierrez C, Weiss H, et al. 2007. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-Targeted therapy. J. Natl. Cancer Inst. 99:694-705
63. Rimawi MF, Wiechmann LS, Wang YC, et al. 2011. Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. Clin. Cancer Res. 17:1351-61
64. Wang YC, Morrison G, Gillihan R, et al. 2011. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers-role of estrogen receptor and HER2 reactivation. Breast Cancer Res. 13:R121, 1-19
65. Chen AC, Migliaccio I, Rimawi M, et al. 2012. Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-Targeted therapies. Breast Cancer Res. Treat. 134:583-93
66. Funes M, Miller JK, Lai C, et al. 2006. The mucin Muc4 potentiates neuregulin signaling by increasing the cell-surface populations of ErbB2 and ErbB3. J. Biol. Chem. 281:19310-19
67. Price-Schiavi SA, Jepson S, Li P, et al. 2002. Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int. J. Cancer 99:783-91
68. Raina D, Uchida Y, Kharbanda A, et al. 2013. Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells. Oncogene 33:3422-31
69. Fessler SP, Wotkowicz MT, Mahanta SK, Bamdad C. 2009. MUC1 is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells. Breast Cancer Res. Treat. 118:113-24
70. Rimawi MF, Mayer IA, Forero A, et al. 2013. Multicenter phase II study of neoadjuvant lapatinib and trastuzumabwith hormonal therapy andwithout chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J. Clin. Oncol. 31:1726-31
71. Xia W, Bacus S, Hegde P, et al. 2006. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc. Natl. Acad. Sci. USA 103:7795-800
72. Giuliano M, Wang Y-C, Gutierrez C, et al. 2012. Parallel upregulation of Bcl2 and estrogen receptor (ER) expression in HER2+ breast cancer patients treated with neoadjuvant lapatinib. Proc. Thirty-Fifth Annual CTRC-AACR San Antonio Breast Cancer Symp., Cancer Res. 72(Suppl.):Abstr. S5-8
73. XiaW, Bacus S, Husain I, et al. 2010. Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA. Mol. Cancer Ther. 9:292-99
74. Miller TW, Rexer BN, Garrett JT, Arteaga CL. 2011. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res. 13:224, 1-12
75. Brady SW, Zhang J, Seok D, et al. 2014. Enhanced PI3K p110alpha signaling confers acquired lapatinib resistance that can be effectively reversed by a p110alpha-selective PI3K inhibitor. Mol. Cancer Ther. 13:60-70
76. Xia W, Husain I, Liu L, et al. 2007. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res. 67:1170-75
77. Dave B, Migliaccio I, Gutierrez MC, et al. 2011. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J. Clin. Oncol. 29:166-73
78. Perez EA, Dueck AC, McCullough AE, et al. 2013. Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. J. Clin. Oncol. 31:2115-22
79. Contreras A, Herrera S, Wang T, et al. 2013. PIK3CA mutations and/or low PTEN predict resistance to combined anti-HER2 therapywith lapatinib and trastuzumab andwithout chemotherapy in TBCRC006, a neoadjuvant trial of HER2-positive breast cancer patients. Proc. Thirty-Sixth Annual CTRC-AACR San Antonio Breast Cancer Symp., Cancer Res. 73(24 Suppl.):Abstr. PD1-2
80. Loibl S, Denkert C, Schneeweis A, et al. 2013. PIK3CA mutation predicts resistance to anti-HER2/chemotherapy in primary HER2-positive/hormone-receptor-positive breast cancer-prospective analysis of 737 participants of the GeparSixto and GeparQuinto studies. Proc. Thirty-Sixth Annu. CTRC-AACR San Antonio Breast Cancer Symp., Cancer Res. 73:Abstr. S4-06
81. Baselga J, Majewski I, Nuciforo PG, et al. 2013. PI3KCA mutations and correlation with pCR in the NeoALTTO trial (BIG 01-06). Proc. 17th ECCO-38th ESMO-32nd ESTRO European Cancer Congress, Amsterdam, Eur. J. Cancer 49 (Suppl.): Abstr. 1859
82. Zhang S, Huang WC, Li P, et al. 2011. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat. Med. 17:461-69
83. Scaltriti M, Eichhorn PJ, Cortes J, et al. 2011. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc. Natl. Acad. Sci. USA 108:3761-66
84. Nahta R, Takahashi T, Ueno NT. 2004. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res. 64:3981-86
85. Beano A, Signorino E, Evangelista A, et al. 2008. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J. Transl. Med. 6:25, 1-10
86. Varchetta S, Gibelli N, Oliviero B, et al. 2007. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res. 67:11991-99
87. Musolino A, Naldi N, Bortesi B, et al. 2008. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positivemetastatic breast cancer. J. Clin. Oncol. 26:1789-96
88. Mellor JD, Brown MP, Irving HR, et al. 2013. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J. Hematol. Oncol. 6:1, 1-10
89. Loi S, Michiels S, Salgado R, et al. 2013. Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stageHER2-positive breast cancer (HER2+ BC). Cancer Res. 73(24 Suppl.):Abstr. S1-05
90. KohrtHE, Houot R, Weiskopf K, et al. 2012. Stimulation of natural killer cells with aCD137-specific antibody enhances trastuzumab efficacy in xenotransplantmodels of breast cancer. J. Clin. Invest. 122:1066-75
91. Yang XH, Flores LM, Li Q, et al. 2010. Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists. Cancer Res. 70:2256-63
92. Huang C, Park CC, Hilsenbeck SG, et al. 2011. β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res. 13:R84, 1-15
93. GuoW, Pylayeva Y, Pepe A, et al. 2006. Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell 126:489-502
94. Zoeller J, Bronson R, Gilmer T, et al. 2012. Basement membrane localized tumor cells are protected from HER2-Targeted therapy in vivo. Proc. Thirty-Fifth Annual CTRC-AACR San Antonio Breast Cancer Symp., Cancer Res. 72(Suppl.):Abstr. P4-08-5
95. UntchM, Loibl S, Bischoff J, et al. 2012. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-Taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 13:135-44
96. Baselga J, Bradbury I, Eidtmann H, et al. 2012. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379:633-40
97. Robidoux A, Tang G, Rastogi P, et al. 2013. Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41. Lancet Oncol. 14:1183-92
98. Gianni L, Pienkowski T, Im YH, et al. 2012. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (Neo-Sphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 13:25-32
99. Schneeweiss A, Chia S, HickishT, et al. 2013. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann. Oncol. 24:2278-84
100. de Azambuja E, Piccart M. 2011. Adjuvant treatment of ERBB2 positive breast cancer. In Diseases of the Breast, ed. M Morrow, JR Harris, ME Lippman, CK Osborne, pp. 657-67. Philadelphia: Lippincott Williams & Wilkins. 4th ed.